Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

Open platform

Avacta says AVA6103 drug candidate achieves proof of mechanism in Phase 1 trial

By Reuters News16:36 (UTC), 16 September 2026 Updated

Sept 16 (Reuters) - Avacta Group PLC AVCT.L:

AVACTA ACHIEVES CLINICAL PROOF OF MECHANISM FOR THE NEXT GENERATION OF PRE|CISION® MEDICINES WITH AVA6103 (FAP-EXD) IN THE PHASE 1 FOCUS-01 TRIAL
AVACTA THERAPEUTICS - AVA6103 DEMONSTRATES CLEAN SAFETY PROFILE AT DOSE LEVEL 50% ABOVE MTD OF CONVENTIONAL EXATECAN
AVACTA THERAPEUTICS - FIRST EFFICACY DATA FROM FOCUS-01 TRIAL WITH AVA6103 EXPECTED IN H1 2027

Further company coverage: AVCT.L

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.